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Interleukins (IL) and other mediators of immune 
response are essential in inflammation, but 
also in the pathophysiology of AD: (1) IL immu-
noreactivity is elevated in AD brains [2]; (2) 
Introduction
Inflammation plays a relevant role in the devel-
opment of Alzheimer’s disease (AD) [1]. 
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Abstract: Objective: Neuroinflammation contributes to the pathogenesis of sporadic Alzheimer’s disease (AD). Varia-
tions in genes relevant to inflammation may be candidate genes for AD risk. Whole-genome association studies 
have identified relevant new and known genes. Their combined effects do not explain 100% of the risk, genetic in-
teractions may contribute. We investigated whether genes involved in inflammation, i.e. PPAR-α, interleukins (IL) IL-
1α, IL-1β, IL-6, and IL-10 may interact to increase AD risk. Methods: The Epistasis Project identifies interactions that 
affect the risk of AD. Genotyping of single nucleotide polymorphisms (SNPs) in PPARA, IL1A, IL1B, IL6 and IL10 was 
performed. Possible associations were analyzed by fitting logistic regression models with AD as outcome, controlling 
for centre, age, sex and presence of apolipoprotein ε4 allele (APOEε4). Adjusted synergy factors were derived from 
interaction terms (p<0.05 two-sided). Results: We observed four significant interactions between different SNPs in 
PPARA and in interleukins IL1A, IL1B, IL10 that may affect AD risk. There were no significant interactions between 
PPARA and IL6. Conclusions: In addition to an association of the PPARA L162V polymorphism with the AD risk, we 
observed four significant interactions between SNPs in PPARA and SNPs in IL1A, IL1B and IL10 affecting AD risk. 
We prove that gene-gene interactions explain part of the heritability of AD and are to be considered when assessing 
the genetic risk. Necessary replications will require between 1450 and 2950 of both cases and controls, depending 
on the prevalence of the SNP, to have 80% power to detect the observed synergy factors. 
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polymorphism of the IL10 gene may be a risk 
factor for AD [26] (Zhang et al. 2011).  
The inconsistency of previously observed asso-
ciations may be the consequence of variable 
epistatic interactions between various genes in 
different populations. The Epistasis Project 
was designed to focus on such possible inter-
actions. We investigated whether genes 
involved in inflammation, e.g. the PPARA gene, 
interact with IL1A, IL1B, IL6 and IL10 to 
increase the risk of AD. 
Materials and methods
Study population
The Epistasis Project aims primarily to replicate 
interactions that have been reported to affect 
the risk of AD. Sample-sets were drawn from 
narrow geographical regions with relatively 
homogeneous, Caucasian populations, by 
seven AD research groups: Bonn, Bristol, 
Nottingham, Oxford (OPTIMA), Oviedo, 
Rotterdam and Santander. Sample characteris-
tics by geographical region are given in 
Supplementary Table 1. All AD cases were diag-
nosed “definite” or “probable” by CERAD [27] or 
NINCDS-ADRDA criteria [28]. AD cases were 
sporadic, i.e. possible autosomal dominant 
cases were excluded, based on family history. 
The median ages (interquartile ranges) of AD 
cases were 79.0 (73.0-85.2) and of controls 
were 76.9 (71.3-83.0) years. Research ethical 
approval was obtained by each of the partici-
pating groups (Supplementary Table 2). 
Comprehensive details of our sample-sets are 
given elsewhere [29].
Genotyping
Genotyping for the six centres other than 
Rotterdam was performed at the Wellcome 
Trust Sanger Institute. The Rotterdam samples 
were genotyped locally, as previously described 
[30,31]. For this study, Rotterdam genotyped 
seven single nucleotide polymorphisms (SNPs), 
rs135551, rs1800206, rs17561, rs1143634, 
rs2069837, rs1800896 and rs3024505, and 
imputed six, rs4253766, rs1800587, 
rs3783550, rs16944, rs1800795 and 
rs1800871.
Statistical analysis
We analysed possible associations by fitting 
logistic regression models with AD diagnosis as 
interleukins (IL-1β, IL-6) are significantly 
increased in peripheral blood of AD subjects 
compared with controls [3],  (3) in vivo and in 
vitro studies indicate that IL-1 may trigger AD 
pathogenesis [4,5]; (4) IL-6 may induce AD-type 
phosphorylation of tau proteins [6]. The peroxi-
some proliferator activated receptor alpha 
(PPAR-α) is involved in inflammation and AD 
through several pathways: (1) It is part of the 
steroid hormone receptor superfamily [7]; (2) 
as a heterodimer with the retinoid X receptor 
(RXR) it binds to the regulatory region of target 
genes that may be involved in inflammation 
control [8,9]; (3) The expression of the PPARα 
gene (PPARA) is significantly reduced in AD 
brains [10]; (4) PPARα agonists inhibit the 
β-amyloid-stimulated expression of tumor 
necrosis factor (TNF-α) and IL-6 reporter genes 
in monocytes [11].
Large scale genome-wide association studies 
have identified several already known and 
some new genes relevant to AD [12, 13]. 
However, their combined main effects do not 
explain 100% of the prevalence of AD. Genetic 
interactions may thus contribute to the devel-
opment of AD, but are difficult to assess in 
whole genome association studies assessing 
up to a million genetic variations at one time 
without specific a priori hypotheses. 
Interactions of variations in genes relevant to 
inflammation, such as the PPAR and IL genes, 
may be reasonable candidates that may influ-
ence the course of AD. They are not only sup-
ported by pathophysiological evidence, as indi-
cated above, but also by previous genetic 
association studies: (1) Associations of the 
PPARA L162V polymorphism with the risk of AD 
have been observed [14]; (2) Polymorphisms in 
IL1A gene have been associated with the risk 
[15,16] and age-at-onset of AD [17]; however, 
this has not been confirmed by others [18-21]; 
(3) Variations in IL1B have been found to be 
associated with AD [22,21]; again this result is 
not unopposed [18]; (4) Bagli et al. [23] report-
ed that polymorphisms of the gene encoding 
the inflammatory cytokine, IL-6, were related to 
soluble interleukin-6 receptor levels in AD; (5) 
Associations between polymorphisms in the 
IL6 gene and its promoter may influence the 
risk of AD [24] (6) A genetic variation of the 
inflammatory cytokine gene IL6, delayed the 
onset and reduced the risk of sporadic AD [25]; 
(7) A recent meta-analysis suggested that a 
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the structure of linkage disequilibrium of the 
three in PPARA. Of the six SNPs shown in Table 
1, only PPARA L162V was independently asso-
ciated with AD: odds ratio for LL vs VL+VV = 1.3 
(95% confidence interval: 1.04 – 1.5, p = 0.02), 
as previously reported [31]. All the other main 
effects, on both dominant and recessive mod-
els, were of non-significant odds ratios ≤ 1.3. 
Genotype distributions from each of the seven 
centres are shown in Supplementary Table 3. 
Hardy-Weinberg (HW) analysis was performed 
for the six SNPs in Table 1. Of those 24 analy-
ses, two resulted in HW disequilibrium, where-
as one would be expected by chance. The HW 
disequilibrium in PPARA L162V in AD cases, 
has previously been shown to be due to hetero-
sis, reflecting a true effect of this polymorphism 
on disease risk [31].
We looked for interactions in AD risk between 
the three PPARA SNPs (rs135551, rs1800206 
and rs4253766) and ten SNPs in or near IL1A 
(rs1800587, rs3783550 and rs17561), IL1B 
(rs16944 and rs1143634), IL6 (rs1800795 
and rs2069837) and IL10 (rs1800896, 
rs1800871 and rs3024505). We found four 
nominally significant interactions overall (at p < 
0.05) and two close to nominal significance (p ≤ 
0.06) (Table 2). One other interaction, between 
PPARA rs4253766 CC+CT and IL10 rs1800871 
the outcome  variable, controlling for study cen-
tre, age, sex and the ε4 allele of apolipoprotein 
E (APOEε4) in all analyses, using R Version 
2.13.0 (R Foundation for Statistical Computing, 
Vienna, Austria). The adjusted synergy factors 
[32] were derived from the interaction terms in 
those models. We controlled for heterogeneity 
among centres and over-dispersion as 
described before [31]. 
We studied three single nucleotide polymor-
phisms (SNPs) in PPARA, three in IL1A, two in 
IL1B, two in IL6 and three in IL10 (below). 
Power calculations were based on the observed 
synergy factor values. Comparisons of allelic 
frequencies between North Spain and North 
Europe were obtained using Fisher’s exact test. 
Linkage disequilibrium data were estimated 
using the R library, genetics (http://
cran.r-project.org/web/packages/genetics/
index.html). All tests of significance and power 
calculations were p<0.05, two-sided.
Results
Inflammation-related interactions
Six of the 13 studied SNPs were involved in 
potential interactions (below); thus, only data 
from those six are reported here. Table 1 shows 
the allelic frequencies of those six SNPs and 
Table 1. Studied SNPs* 







With North Europe† North Spain†





rs135551        Intron 2 G/A
rs1800206      L162V
rs4253766      Intron 6 C/T
rs3783550      Intron 6 A/C
rs16944          -971 G/A
rs1800896      -1082 G/A
27.7% (A)
  
































*Data are only supplied for those cytokine gene SNPs that showed nominally significant interactions with PPARA SNPs
† North Europe here comprises Bonn, Bristol, Nottingham, Oxford and Rotterdam; North Spain comprises Oviedo and Santander
Significant differences are in bold
SNP = single nucleotide polymorphism; PPARA, IL1A, IL1B and IL10 are the genes for peroxisome proliferator-activated 
receptor-α, interleukin-1α, interleukin-1β and interleukin-10, respectively; D’ = ratio of observed linkage disequilibrium to maxi-
mum possible linkage disequilibrium, r = correlation coefficient
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Possible interaction of ILs and PPARA
Activation of microglia results in the synthesis 
and secretion of the proinflammatory cytokines 
IL1B, IL-6, and TNF-α, and the chemokine mac-
rophage chemotactic protein-1 [33]. The inter-
action of microglia or monocytes with beta-
amyloid (Aβ) fibrils elicits the activation of a 
complex tyrosine kinase-based signal trans-
duction cascade, leading to stimulation of mul-
tiple independent signalling pathways and ulti-
mately to changes in pro-inflammatory gene 
expression. The Aβ-stimulated expression of 
pro-inflammatory genes in myeloid lineage cells 
is antagonized by the action of a family of 
ligand-activated nuclear hormone receptors, 
the peroxisome proliferator-activated receptors 
(PPARs) [11].  Those authors report that THP-1 
monocytes express the PPAR-γ isoform and 
lower levels of the PPAR-α and PPAR-δ iso-
forms. Their study explored the action of the 
PPAR-α isoform and found that PPAR-α ago-
nists inhibited the Aβ-stimulated expression of 
TNF-α and IL-6 reporter genes in a dose-depen-
dent manner. Moreover, the PPAR-α agonist, 
WY14643, inhibited macrophage differentia-
tion and COX-2 gene expression. They conclude 
that PPAR-α acts to suppress a diverse array of 
inflammatory responses in monocytes. 
CC, was nominally significant overall (synergy 
factor = 4.8, p = 0.04) and consistent between 
North Europe and North Spain (synergy fac-
tors=5.3 and 5.4, respectively), but was reject-
ed due to heterogeneity between the four coun-
tries: Britain, Germany, Spain and the 
Netherlands.
Discussion 
We found a weak association of the PPARA 
L162V polymorphism with the risk of AD, as 
previously reported [14,31]. We also found four 
nominally significant interactions and two close 
to nominal significance (Table 1 and 2). By 
“nominally significant” we mean that these 
results would not survive correction for multiple 
testing. However, there was consistency 
between the findings for North Europe and 
North Spain (Table 2). Nevertheless, we sug-
gest that replication is needed before these 
results may be considered valid. Such replica-
tion would require between 1450 and 2950 
cases and equivalent numbers of controls, 
depending on the interaction, to have 80% 
power to detect synergy factors (at p < 0.05) of 
the effect sizes described in this paper and 
SNP prevalences as found in our samples 
(Table 2).





Synergy factor (95% confidence interval, p)
Overall North Europe† North Spain†
rs1800206
CC vs CG + GG
IL1A rs3783550
AA vs AC + CC
IL1B rs16944
GG + GA vs AA
IL10 rs1800896











CC vs CT + TT
IL1A rs3783550
AC + CC vs AA 
IL10 rs1800896








GG vs GA + AA
IL1B rs16944
GG vs GA + AA
1.3 (0.99-1.7, 0.06) 1.3 (0.96-1.8, 0.09) 1.4 (0.75-2.5, 0.32)
† North Europe here comprises Bonn, Bristol, Nottingham, Oxford and Rotterdam; North Spain comprises Oviedo and Santander
Nominally significant interactions are in bold; SNP = single nucleotide polymorphism; PPARA, IL1A, IL1B and IL10 are the genes 
for peroxisome proliferator-activated receptor-α, interleukin-1α, interleukin-1β and interleukin-10, respectively.
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Supplementary Table 1. Sample characteristics by geographical region 
Region Subjects Age subsets Sex ratio APOEε4
< 75 years > 75 years Totals % women p (controls
vs AD)   
Frequency p (controls












































AD = Alzheimer’s Disease; APOEε4 = the ε4 allele of the apolipoprotein E gene.                                                                                                                                 
Quality control of genotyping reduced the numbers below the above figures (see Table 3). Fuller details, including characteris-
tics of each of the seven sample-sets, are given in Combarros et al 2009 (Combarros et al., 2009). *Difference between North 
Europe and North Spain: p < 0.0001.
Supplementary Table 2. Research ethic approval
Group Committee
Bonn Ethics Review Board of the University of Bonn
Bristol Frenchay Local Research Ethics committee, Bristol
Nottingham Nottingham Research Committee 2 (NHS)
OPTIMA Central Oxford Ethics Committee No 1656
Oviedo Ethical Committee of the Hospital Central de Asturias
Rotterdam Medical Ethical Committee of the Erasmus MC
Santander Ethical Committee of the University Hospital “Marqués de Valdecilla”, Santander
Supplementary Table 3. Genotype distributions in controls and AD cases of seven centres
Gene SNP Centre Controls AD
PPARA rs135551
= Intron 2
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PPARA rs4253766
= Intron 6
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Bonn
Bristol
Nottingham
OPTIMA
Oviedo
Rotterdam
Santander
Totals
GG
45
12
22
58
25
1339
66
1567
AG
109
25
29
123
61
2538
185
3070
AA
62
15
25
60
24
1233
136
1555
GG
54
45
21
72
24
120
38
374
AG
118
72
28
112
97
190
182
799
AA
73
45
18
53
65
81
91
426
